帕金森病胃肠动力障碍发病机制和治疗的研究进展

doi:10.13481/j.1671-587X.20240135

Abstract

Abstract:

The gastrointestinal motility disorder of the patients with Parkinson’s disease (PD) occurs in the early stages of this disease, even before the onset of motor symptoms. The gastrointestinal motility disorder is one type of gastrointestinal dysfunction, not only affect the absorption of medication, exacerbating the progression of PD, but also severely impact the quality of life of the patients. Therefore, it is essential to find new therapeutic targets to alleviate PD-induced gastrointestinal dysmotility in order to improve the progression of the disease and the quality of life of the patients. The gastrointestinal motility function is highly dependent on the health of the gut and central nervous regulating the gastrointestinal movements. A healthy gut is closely related to the integrity of the intestinal barrier, gut microbiota, neuroinflammation, and the normal function of enteric neurons responsible for the contraction and relaxation of the gastrointestinal tract. The gut function of the PD patients is compromised to some extent. This review summarizes the effects of the enteric nervous system, central nervous system, and gut microbiota on the development of gastrointestinal motility disorder of the PD patients;it also outlines the current therapeutic methods available and their limitations, with the aim of providing the new insights into the treatment of gastrointestinal motility disorder of the PD patients.

Key words: Parkinson’s disease, Gastrointestinal motility disorder, Enteric nervous system, Gut microbiota

CLC Number:

R742.5

Can ZHANG,Yan CHEN. Research progress in pathogenesis and treatment of gastrointestinal motility disorders in Parkinson’s disease[J].Journal of Jilin University(Medicine Edition), 2024, 50(1): 280-287.

References 59

1	HAN M N， FINKELSTEIN D I， MCQUADE R M， et al. Gastrointestinal dysfunction in Parkinson’s disease： current and potential therapeutics［J］. J Pers Med， 2022， 12（2）： 144.
2	ALBUQUERQUE J C S， MENDES T S， BRANDÃO M G S A， et al. Structural bases of gastrointestinal motility changes in Parkinson’s disease： study in rats［J］.Braz Arch Dig Surg，2021，33（3）：e1548.
3	NEMADE D， SUBRAMANIAN T， SHIVKUMAR V. An update on medical and surgical treatments of Parkinson’s disease［J］. Aging Dis， 2021， 12（4）： 1021-1035.
4	WARNECKE T， SCHÄFER K H， CLAUS I， et al. Gastrointestinal involvement in Parkinson’s disease： pathophysiology， diagnosis， and management［J］. NPJ Parkinsons Dis， 2022， 8（1）： 31.
5	SAFARPOUR D， SHARZEHI K， PFEIFFER R F. Gastrointestinal dysfunction in Parkinson’s disease［J］. Drugs， 2022， 82（2）： 169-197.
6	CUNNANE S C， TRUSHINA E， MORLAND C，et al. Brain energy rescue： an emerging therapeutic concept for neurodegenerative disorders of ageing［J］. Nat Rev Drug Discov， 2020， 19（9）： 609-633.
7	ANDERSON G， NOORIAN A R， TAYLOR G， et al. Loss of enteric dopaminergic neurons and associated changes in colon motility in an MPTP mouse model of Parkinson’s disease［J］.Exp Neurol，2007，207（1）： 4-12.
8	SINGARAM C， ASHRAF W， GAUMNITZ E A，et al. Dopaminergic defect of enteric nervous system in Parkinson’s disease patients with chronic constipation［J］. Lancet， 1995， 346（8979）： 861-864.
9	GHAISAS S， LANGLEY M R， PALANISAMY B N， et al. MitoPark transgenic mouse model recapitulates the gastrointestinal dysfunction and gut-microbiome changes of Parkinson’s disease［J］. Neurotoxicology， 2019， 75： 186-199.
10	NAKAMORI H， NODA K， MITSUI R， et al. Role of enteric dopaminergic neurons in regulating peristalsis of rat proximal colon［J］. Neurogastroenterol Motil， 2021， 33（9）： e14127.
11	SINEN O， ÖZKAN A， AĞAR A，et al.Neuropeptide-S prevents 6-OHDA-induced gastric dysmotility in rats［J］. Brain Res， 2021， 1762： 147442.
12	GIANCOLA F， TORRESAN F， REPOSSI R， et al. Downregulation of neuronal vasoactive intestinal polypeptide in Parkinson’s disease and chronic constipation［J］. Neurogastroenterol Motil，2017，29（5）.DOI：10.1111/nmo.12995 . doi: 10.1111/nmo.12995
13	VERGNOLLE N， CIRILLO C. Neurons and glia in the enteric nervous system and epithelial barrier function［J］. Physiology， 2018， 33（4）： 269-280.
14	CLAIREMBAULT T， KAMPHUIS W， LECLAIR-VISONNEAU L， et al. Enteric GFAP expression and phosphorylation in Parkinson’s disease［J］. J Neurochem， 2014， 130（6）： 805-815.
15	BENVENUTI L， D’ANTONGIOVANNI V， PELLEGRINI C， et al. Enteric glia at the crossroads between intestinal immune system and epithelial barrier： implications for parkinson disease［J］. Int J Mol Sci， 2020， 21（23）： 9199.
16	NAIR A T， RAMACHANDRAN V， JOGHEE N M， et al. Gut microbiota dysfunction as reliable non-invasive early diagnostic biomarkers in the pathophysiology of Parkinson’s disease： a critical review［J］. J Neurogastroenterol Motil， 2018， 24（1）： 30-42.
17	PEREZ-PARDO P， GROBBEN Y， WILLEMSEN-SEEGERS N， et al. Pharmacological validation of TDO as a target for Parkinson’s disease［J］. FEBS J， 2021， 288（14）： 4311-4331.
18	ISOOKA N， MIYAZAKI I， ASANUMA M. Glial cells as possible targets of neuroprotection through neurotrophic and antioxidative molecules in the central and enteric nervous systems in Parkinson’s disease［J］. Acta Med Okayama， 2021， 75（5）： 549-556.
19	GANG C， DU Y Z， XUE L， et al. Lower GDNF serum level is a possible risk factor for constipation in patients with parkinson disease： a case-control study［J］. Front Neurol， 2021， 12： 777591.
20	KUJAWSKA M， JODYNIS-LIEBERT J. What is the evidence that Parkinson’s disease is a prion disorder， Which originates in the gut？［J］. Int J Mol Sci， 2018， 19（11）： 3573.
21	GREENE J G. Causes and consequences of degeneration of the dorsal motor nucleus of the vagus nerve in Parkinson’s disease［J］. Antioxid Redox Signal， 2014， 21（4）： 649-667.
22	CHALLIS C， HORI A， SAMPSON T R，et al.Gut-seeded α-synuclein fibrils promote gut dysfunction and brain pathology specifically in aged mice［J］. Nat Neurosci， 2020， 23（3）： 327-336.
23	ANSELMI L， TOTI L， BOVE C， et al. A nigro-vagal pathway controls gastric motility and is affected in a rat model of Parkinsonism［J］.Gastroenterology，2017，153（6）： 1581-1593.
24	YANG Y L， RAN X R， LI Y， et al. Expression of dopamine receptors in the lateral hypothalamic nucleus and their potential regulation of gastric motility in rats with lesions of bilateral substantia nigra［J］. Front Neurosci， 2019， 13： 195.
25	CHIU W H， KOVACHEVA L， MUSGROVE R E，et al.α-Synuclein-induced Kv4 channelopathy in mouse vagal motoneurons drives nonmotor parkinsonian symptoms［J］. Sci Adv， 2021， 7（11）： eabd3994.
26	SAMPSON T R， DEBELIUS J W， THRON T， et al. Gut microbiota regulate motor deficits and neuroinflammation in a model of Parkinson’s disease［J］. Cell， 2016， 167（6）： 1469-1480.
27	KESHAVARZIAN A， GREEN S J， ENGEN P A，et al. Colonic bacterial composition in Parkinson’s disease［J］. Mov Disord， 2015， 30（10）： 1351-1360.
28	YEMULA N， DIETRICH C， DOSTAL V， et al. Parkinson’s disease and the gut： symptoms， nutrition， and microbiota［J］. J Parkinsons Dis， 2021，11（4）： 1491-1505.
29	LIN C H， CHEN C C， CHIANG H L， et al. Altered gut microbiota and inflammatory cytokine responses in patients with Parkinson’s disease［J］. J Neuroinflammation， 2019， 16（1）： 129.
30	WANG Q， LUO Y Q， CHAUDHURI KRAY， et al. The role of gut dysbiosis in Parkinson’s disease： mechanistic insights and therapeutic options［J］. Brain， 2021， 144（9）： 2571-2593.
31	VISCARDI L H， IMPARATO D O， BORTOLINI M C，et al. Ionotropic receptors as a driving force behind human synapse establishment［J］. Mol Biol Evol， 2021， 38（3）： 735-744.
32	PESCE M， CARGIOLLI M， CASSARANO S， et al. Diet and functional dyspepsia： clinical correlates and therapeutic perspectives［J］. World J Gastroenterol， 2020， 26（5）： 456-465.
33	ZUBCEVIC J， RICHARDS E M， YANG T， et al. Impaired autonomic nervous system-microbiome circuit in hypertension［J］. Circ Res， 2019， 125（1）： 104-116.
34	POLITIS M， NICCOLINI F. Serotonin in Parkinson’s disease［J］. Behav Brain Res， 2015， 277： 136-145.
35	CIRSTEA M S， YU A C， GOLZ E， et al. Microbiota composition and metabolism are associated with gut function in Parkinson’s disease［J］. Mov Disord， 2020， 35（7）： 1208-1217.
36	ROMO-VAQUERO M， FERNÁNDEZ-VILLALBA E， GIL-MARTINEZ A L， et al. Urolithins： potential biomarkers of gut dysbiosis and disease stage in Parkinson’s patients［J］. Food Funct， 2022， 13（11）： 6306-6316.
37	ELFIL M， KAMEL S， KANDIL M， et al. Implications of the gut microbiome in Parkinson’s disease［J］. Mov Disord， 2020， 35（6）： 921-933.
38	SHINDE T， PERERA A P， VEMURI R， et al. Synbiotic supplementation with prebiotic green banana resistant starch and probiotic Bacillus coagulans spores ameliorates gut inflammation in mouse model of inflammatory bowel diseases［J］.Eur J Nutr，2020，59（8）： 3669-3689.
39	LOUIS P， HOLD G L， FLINT H J. The gut microbiota， bacterial metabolites and colorectal cancer［J］. Nat Rev Microbiol， 2014， 12（10）： 661-672.
40	JIANG X P， GU S S， LIU D， et al. Lactobacillus brevis 23017 relieves mercury toxicity in the colon by modulation of oxidative stress and inflammation through the interplay of MAPK and NF-κB signaling cascades［J］. Front Microbiol， 2018， 9： 2425.
41	KLANN E M， DISSANAYAKE U， GURRALA A， et al. The gut-brain axis and its relation to Parkinson’s disease： a review［J］. Front Aging Neurosci， 2021， 13： 782082.
42	DUTTON J S， HINMAN S S， KIM R， et al. Primary cell-derived intestinal models： recapitulating physiology［J］.Trends Biotechnol，2019，37（7）： 744-760.
43	ALMANSOUR K， TAVERNER A， TURNER J R， et al. An intestinal paracellular pathway biased toward positively-charged macromolecules［J］. J Control Release， 2018， 288： 111-125.
44	CHUNG J Y， JEONG J H， SONG J. Resveratrol modulates the gut-brain axis： focus on glucagon-like peptide-1， 5-HT， and gut microbiota［J］. Front Aging Neurosci， 2020， 12： 588044.
45	SONG K H， JUNG H K， KIM H J， et al. Clinical practice guidelines for irritable bowel syndrome in Korea， 2017 revised edition［J］. J Neurogastroenterol Motil， 2018， 24（2）： 197-215.
46	WANG Z N， ZHAO Y Z. Gut microbiota derived metabolites in cardiovascular health and disease［J］. Protein Cell， 2018， 9（5）： 416-431.
47	KUAI X Y， YAO X H， XU L J， et al. Evaluation of fecal microbiota transplantation in Parkinson’s disease patients with constipation［J］. Microb Cell Fact， 2021， 20（1）： 98.
48	HUANG H L， XU H M， LUO Q L， et al. Fecal microbiota transplantation to treat Parkinson’s disease with constipation： a case report［J］. Medicine， 2019， 98（26）： e16163.
49	PINI A， GARELLA R， IDRIZAJ E， et al. Glucagon-like peptide 2 counteracts the mucosal damage and the neuropathy induced by chronic treatment with cisplatin in the mouse gastric fundus［J］. Neurogastroenterol Motil， 2016， 28（2）： 206-216.
50	ZHANG Z J， HAO L， SHI M， et al. Neuroprotective effects of a GLP-2 analogue in the MPTP Parkinson’s disease mouse model［J］. J Parkinsons Dis，2021，11（2）： 529-543.
51	FORD N A， LIU A G. The forgotten fruit： a case for consuming avocado within the traditional mediterranean diet［J］. Front Nutr， 2020， 7： 78.
52	QUIGLEY E M M. Nutraceuticals as modulators of gut microbiota： role in therapy［J］. Br J Pharmacol， 2020， 177（6）： 1351-1362.
53	MOLNAR J， MALLONEE C J， STANISIC D， et al. Hidradenitis suppurativa and 1-carbon metabolism： role of gut microbiome， matrix metalloproteinases， and hyperhomocysteinemia［J］. Front Immunol， 2020， 11： 1730.
54	RUSCH C， BEKE M， TUCCIARONE L， et al. Mediterranean diet adherence in people with Parkinson’s disease reduces constipation symptoms and changes fecal microbiota after a 5-week single-arm pilot study［J］. Front Neurol， 2021， 12： 794640.
55	YAO J P， CHEN L P， XIAO X J， et al. Effectiveness and safety of acupuncture for treating functional constipation： an overview of systematic reviews［J］. J Integr Med， 2022， 20（1）： 13-25.
56	ZENG B Y， ZHAO K C. Effect of acupuncture on the motor and nonmotor symptoms in Parkinson’s disease： a review of clinical studies［J］. CNS Neurosci Ther， 2016， 22（5）： 333-341.
57	SONG B J， CHANG Y Y， LI Y， et al. Effects of transcutaneous electrical acupoint stimulation on the postoperative sleep quality and pain of patients after video-assisted thoracoscopic surgery： a prospective， randomized controlled trial［J］. Nat Sci Sleep， 2020， 12： 809-819.
58	ZHANG S， LI S， LIU Y， et al. Electroacupuncture via chronically implanted electrodes improves gastric dysmotility mediated by autonomic-cholinergic mechanisms in a rodent model of functional dyspepsia［J］. Neurogastroenterol Motil， 2018， 30（10）： e13381.
59	LEI W， ZHAO C C， SUN J S， et al. Electroacupuncture ameliorates intestinal barrier destruction in mice with bile duct ligation-induced liver injury by activating the cholinergic anti-inflammatory pathway［J］. Neuromodulation， 2022，25（8）：1122-1133.

[1]	Qian LI,Chunyang KANG,Xiaoyang LIU,Libo WANG,Jiajun CHEN,Jia LI. Juvenile Parkinson’s disease caused by PRKN gene compound heterozygous mutation: A case report and literature review [J]. Journal of Jilin University(Medicine Edition), 2024, 50(1): 248-253.
[2]	Xiaodong WEN,Chunling WANG,Yuanjing JIANG,Xinmei ZHOU,Yi ZHANG,Yuan WU. Effect of fructus mume total flavone on injury of SH-SY5Y cells induced by MPP⁺ through regulating miR-145-3p expression and its mechanism [J]. Journal of Jilin University(Medicine Edition), 2023, 49(6): 1415-1423.
[3]	Chuan LIU,Huan LI,Dawei WANG. Effects of Dendrobium huoshanense polysaccharide on oxidative stress and inflammation in brain tissue of mice with Parkinson’s disease [J]. Journal of Jilin University(Medicine Edition), 2023, 49(1): 110-115.
[4]	Lingling FAN,Shuping DING,Guomin SHEN,Zhihong HU,Aihong REN,Bo DENG. Effect of mediodorsal thalamic nucleus lesions on electrical activity in medial prefrontal cortex of rats with Parkinson’s disease [J]. Journal of Jilin University(Medicine Edition), 2022, 48(6): 1382-1388.
[5]	Qi PAN,Zizhen WANG,Fuyue YE,Wei XING,Jiahan LIN,Jianyue LU,Kun YANG. Effect of proteasome inhibitor lactacystin on oxidative damage of dopaminergic neurons in substantia nigra of rats [J]. Journal of Jilin University(Medicine Edition), 2022, 48(3): 728-733.
[6]	Xiaochen HUANG,Hao LI,Baohua WANG,Kai LI. Protective effect of lidocaine on PC12 cells in Parkinson’s disease model and its mechanism [J]. Journal of Jilin University(Medicine Edition), 2022, 48(3): 638-647.
[7]	Lingna HAN,Chunlei WANG,Yongli CHANG,Li YUAN,Xiaojing LIU. Effect of electrical lesions of lateral habenular nucleus on spatial learning and memory functions in rats with Parkinson’s disease and its mechanism [J]. Journal of Jilin University(Medicine Edition), 2021, 47(5): 1108-1115.
[8]	Xiaofeng LUO,Yao LI,Jiang HU,Chenhao ZHANG. Regulatory effect of gardenoside on sleep disorder in rats with Parkinson’s disease and its mechanism [J]. Journal of Jilin University(Medicine Edition), 2020, 46(6): 1177-1181.
[9]	WANG Chunlei, CHANG Yongli, HAN Lingna. Improvement effects of repeated transcranial direct current stimulation on depression behaviors in rat models of Parkinson's disease and their mechanisms [J]. Journal of Jilin University Medicine Edition, 2018, 44(04): 693-697.
[10]	JIA Xiao-jing, ZHANG Zhi-liang, QU Ya-qin, ZHAI Cheng-wei, YANG Tai-quan, WOLF-DIETER Rausch, GONG Shou-liang. Establishment of cell models of dopaminergic neurons for Parkinson’s disease [J]. Journal of Jilin University(Medicine Edition), 2008, 34(5): 778-781.
[11]	ZHANG Hai-na,HU Guo-hua,CHEN Qiu-hui,SUN Dong,LIU Cai-xia,SUN Ya-juan. Establishment of cell model of Parkinson’〖KG-3〗s disease and toxic effect of rotenone on dopaminergic neurons [J]. J4, 2007, 33(5): 811-814.
[12]	Zhang Yu，XU Hui，ZHANG Ying，HAN Wei，HU Yi-hong，HU Lin-sen. Expression of ERp29 in model of Parkinson’s disease of PC12 cells induced by proteasome inhibitor [J]. J4, 2007, 33(2): 249-252.

Research progress in pathogenesis and treatment of gastrointestinal motility disorders in Parkinson’s disease

RichHTML

PDF (PC)

Like

Knowledge

Abstract

Cite this article

share this article

References 59

Related Articles 12

Metrics

Comments

Recommended 0